Triazavirin

Selected form

Sodium Methylthionitrooxodihydrotriazolotriazinide

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Triazavirin

This section defines the fundamental identity, composition, and general purpose of Triazavirin (Riamilovir), strictly adhering to the scope of a definitional overview.

Property	Description
Active ingredient	Riamilovir (C₅H₃N₆O₃SNa·2H₂O)
Forms	Tablets, Capsules, Solution for injection, Aerosol
Pharmacological class	Direct Acting Antiviral (Azolotriazine class)
General purpose	To treat acute respiratory viral infections (ARVI) and Influenza
Origin	Synthetic

Triazavirin: Identity, Chemical Class, and Origin

Triazavirin is a synthetic, Direct Acting Antiviral drug belonging to the unique azolotriazine (triazole derivative) class of compounds. This classification characterizes its unique chemical mechanism. Its identity is defined by its ability to directly target the cause of viral illness, classifying it as an etiotropic medicine.

This single-component medication, identified by the International Nonproprietary Name (INN) Riamilovir, is a specialized type of antiviral therapy. Its structural classification as a Triazole derivative places it within a distinct chemical lineage, differentiating it from traditional nucleoside analogues. The drug's creation is rooted in synthetic chemistry, distinguishing it from natural-origin medicines.

What is the Active Ingredient in Triazavirin?

The active ingredient in Triazavirin is Sodium Methylthionitrooxodihydrotriazolotriazinide, a complex, synthetically derived compound that constitutes the drug's therapeutic core. It is manufactured as a precise chemical entity, which is a key requirement for its use in various, regulated pharmaceutical preparations.

As a single-component drug, the entire therapeutic function of Triazavirin rests on this specific sodium salt derivative. The medicine is prepared for various routes of administration, offering flexibility in its application, and is formulated into solid forms like tablets and capsules (for oral use), as well as a specialized solution for injection (for parenteral use) and an aerosol preparation (for inhalation).

General Purpose of this Etiotropic Antiviral

The general purpose of this broad-spectrum antiviral agent is to curb the spread and multiplication of certain RNA viruses within the body. It achieves this by actively intervening in the viral reproductive cycle, helping the body to control the overall viral load.

Triazavirin is primarily designed to limit the progression of infectious diseases, addressing the viral cause of conditions such as Influenza (including various strains) and general Acute Respiratory Viral Infections (ARVI). Its antiviral properties against influenza viruses align with its core function to combat the viral pathogen itself, offering a direct therapeutic approach.

Regulatory References

NIH Research Article

What side effects are possible with Triazavirin?

Possible side effects and safety information

The official safety profile for Triazavirin (Riamilovir) is largely defined by strict contraindications and population restrictions, as documented in regulatory-cited literature regarding its use. The classification of adverse reactions is primarily based on System-Organ Classes (SOCs), which outlines the physiological domains potentially affected by the medicine.

Key Regulatory Safety Constraints

The medicine is formally contraindicated in several specific circumstances, meaning it must not be used:

Hypersensitivity: In patients with known individual intolerance (allergy) to the components of the drug.
Severe Organ Impairment: For individuals diagnosed with severe hepatic impairment (liver disease) or severe renal impairment (kidney disease).
Physiological State: For women who are pregnant or currently breastfeeding (lactating).

Adverse Reaction Classification

Regulatory documentation primarily focuses on the potential for effects in one major system class, though specific classifications are limited:

System-Organ Class (SOC)	Documented Adverse Reaction	Frequency Classification
Gastrointestinal Disorders	Dyspepsic disorders (e.g., meteorism)	Very rare

Serious adverse reactions are subject to regulatory monitoring, as their occurrence is an explicit criterion for patient withdrawal from clinical settings; however, the identity of these specific severe events is not publicly classified in regulatory documents.

This structure prioritizes patient safety through mandatory pre-screening against these official restrictions, which are the cornerstone of the drug's risk management profile.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Triazavirin (Riamilovir) overdose focuses on mandatory procedural actions and symptomatic management. Overdose manifestations are primarily described as a potential exacerbation of known adverse reactions, which may include gastrointestinal disturbances such as increased nausea and vomiting.

Official Regulatory Guidance

Classification	Detail (As Stated in Official Documents)
Antidote Availability	No specific drug antidote is known or documented for Triazavirin.
Severe Outcomes	No unique severe or life-threatening outcomes are explicitly detailed in regulatory labels for this overdose.

Required Emergency Actions

Immediate medical intervention is strictly mandated upon suspicion of over-ingestion. Patients must seek immediate medical attention and professional clinical observation is required. The regulatory instructions specify that management is purely symptomatic and supportive treatment and requires continuous monitoring of vital signs.

Supportive measures such as gastric lavage or administration of activated charcoal are noted as potential steps, if appropriate based on the time since ingestion. The regulatory documentation requires hospitalization for observation to ensure patient status stability following any suspected overdose event.

Therapeutic Uses of Triazavirin

What Triazavirin Treats: Main Uses and Benefits

Triazavirin (Riamilovir) is an antiviral medication primarily used to provide symptomatic support for conditions caused by a viral pathogen in the management of acute viral respiratory illnesses. Its application is applied across domains where additional symptomatic support is needed. It is used to help with the symptoms associated with Influenza and general Acute Respiratory Viral Infections (ARVI).

Supporting Stability During Acute Episodes

This medication is relevant in clinical settings that involve acute or unstable symptom patterns, addressing conditions characterized by periods of heightened symptoms. It is used to manage symptom clusters that may become intense or disruptive, such as high fever, pronounced muscle pain, headache, and general malaise. The use of Triazavirin supports the patient during difficult episodes by easing distress and assists with maintaining a sense of stability when symptoms are more noticeable.

Easing the Overall Symptom Load

Triazavirin is applied in scenarios where additional management of discomfort is required, particularly during phases when acute manifestations become more noticeable. This supportive relief contributes to improved comfort during periods of heightened symptoms and helps address the Systemic Intoxication Syndrome. By applying the drug in addressing symptoms related to acute or episodic changes, clinical use supports general well-being during symptomatic phases.

Quick Fact: Relief for Systemic Intoxication
Applied in contexts where short-term symptom management for acute viral distress is appropriate.

Regulatory References

NIH review referencing Russian Ministry of Health approval

Eligibility and Restrictions for Use

The official regulatory profile for Triazavirin (Riamilovir) establishes specific exclusions based on age, reproductive status, and organ function, limiting its use to a defined adult population.

Eligibility Criteria

The medicine is officially approved for use only in adults (18 years and older) who do not have any of the following contraindications.

Classification	Population/Condition
Absolute Contraindication	Children/Adolescents (Under 18 years)
Absolute Contraindication	Pregnancy and Breastfeeding (Use is prohibited)
Organ Dysfunction	Severe Hepatic Impairment (Child-Pugh Grade C)
Organ Dysfunction	Severe Renal Impairment (e.g., GFR le 30 mLcdot min^-1cdot 1.73 m^-2 or dialysis)
Hematological Condition	Severe Anemia (e.g., Hemoglobin < 60 gcdot L^-1)
Hypersensitivity	Known allergy to the drug substance or its components

Official regulatory documents mandate that the drug must not be used in individuals under 18 or in women who are pregnant or breastfeeding. Furthermore, use is prohibited in patients with pre-existing severe organ dysfunction, particularly the liver and kidneys, due to clearance and safety concerns.

What should I know about interactions with other medicines?

Triazavirin Interactions with other medicines and products

Interaction Scope

The regulatory profile of Triazavirin (Riamilovir) is currently defined by the absence of detailed, published interaction studies in the public domain of major international government health authorities. Consequently, the official labeling for the drug does not contain explicit, universally published constraints for co-administration.

Category	Official Regulatory Status (Based on Available Government Documentation)
Medicinal product categories with documented interactions	None explicitly listed. Official data does not provide a categorized list of interacting medicinal products (e.g., in terms of CYP substrates, inducers, or inhibitors).
Specific interacting medicines (if explicitly listed)	None explicitly listed. Specific drug entities requiring use restriction or dose alteration due to a documented interaction are not specified.
Mechanistic basis of interactions	None explicitly stated. The official profile does not detail the mechanistic basis (e.g., specific CYP enzyme or transporter involvement) for drug-drug interactions.
Timing-based interaction rules	None documented. Official label text does not specify mandatory timing separation requirements (e.g., "administer X hours apart") for co-administration.

Resulting Interaction Structure

Official interaction statements:

Official regulatory documentation does not explicitly list specific medicinal products that are contraindicated for co-administration with Triazavirin due to interaction risk.
The regulatory profile does not contain published data detailing Riamilovir's involvement in specific drug metabolic pathways, such as Cytochrome P450 enzyme inhibition or induction.
Official regulatory sources do not explicitly document interactions with non-medicinal substances, including food, alcohol, or specific herbal products.

The overall interaction profile is characterized by a lack of specific constraints, prohibitions, or timing separation requirements based on published drug-drug interaction studies from major government health agencies. This reflects that no specific alterations or restrictions are formally stated in the accessible official documents.

Mechanism of Action

Direct Blockade of Viral Genetic Replication

Triazavirin (Riamilovir) functions as a direct-acting antiviral by targeting the central replication machinery of RNA viruses. The administered compound is a prodrug that requires intracellular biotransformation by host cell kinases to become its active triphosphate metabolite. This activated molecule engages in molecular mimicry, competing with natural guanosine triphosphate (GTP) for incorporation by the viral enzyme RNA-dependent RNA Polymerase (RdRp).

Mechanistic Cascade and Viral Load Modulation

Once incorporated, the drug metabolite causes delayed chain termination, a molecular error that halts the synthesis of the nascent viral RNA strand. This specific inhibition prevents the virus from generating functional genetic material. The consequence of this blockade is a reduction in the production of new, infectious virions within host cells. This etiotropic action physiologically results in the decrease of the systemic viral load and the modulation of viral pathogenesis.

Dosage and Administration Information

How to Use Triazavirin (Riamilovir): General Administration Overview

The administration of Triazavirin is structured around a fixed, short-term protocol aimed at adult patients with acute viral infections. The standard regimen relies on the oral route using the capsule dosage form, although a specialized solution for injection allows for parenteral, likely intravenous, use.

Standard Adult Dosing and Schedule

The standard protocol involves a uniform course of administration to be initiated as soon as possible following symptom onset. The treatment course is typically seven days long. The standard dose unit is 250 mg per capsule, and the entire 750 mg total daily dose is divided and administered three times daily (TID). The fixed dosing schedule maintains the concentration necessary for the prescribed duration.

Administration Protocol

Instruction	Details
Route of Administration	Oral (Primary) or Intravenous (Specialized)
Single Dose Strength	250 mg
Frequency	Three times daily (TID)
Total Duration	Seven days
Target Population	Adult patients only

This framework specifies the dose and timing, reflecting the procedures established for this therapeutic framework. The fixed duration is not typically extended beyond the seven days prescribed for the acute treatment course.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Triazavirin

Evidence for use in Influenza and Acute Respiratory Viral Infections (ARVI)

This section will summarize the types of comprehensive clinical trials and meta-analyses that exist for the drug’s use in these acute conditions, describing what specific clinical measurements were tracked in these short-term studies.

Research has examined the use of Triazavirin in adult patients who have confirmed Influenza and general Acute Respiratory Viral Infections (ARVI), which are conditions associated with acute or disruptive episodes. Studies were conducted during periods of increased symptom activity, and researchers monitored outcomes related to physical discomfort, such as the duration of fever and feelings of general functional imbalance.

Research describes the changes measured during the study period for the observed populations during the short-term, acute phase of the illness. Findings describe patterns observed in the studies related to the timeline of symptom resolution and the monitored incidence of complications. Comparative evidence in a broad global research environment remains limited.

Evidence for Investigational Use in COVID-19

This part will describe the structure of the pilot Randomized Controlled Trials (RCTs) conducted during the pandemic, including the specific composite endpoints and populations of hospitalized adults examined in both treatment and prophylaxis settings.

Research on Triazavirin as a Treatment for Acute COVID-19

Studies explored Triazavirin in hospitalized adult patients with confirmed COVID-19. These were pilot randomized controlled trials (RCTs) where researchers monitored outcomes related to systemic or functional imbalance, such as the time it took for patients to reach a defined endpoint of clinical improvement. However, these reports did not establish a statistically significant difference between the observed patterns in the drug group and the placebo group for the primary outcome. Research on clinical outcomes in this setting appears to be still emerging.

Studies Examining Triazavirin for COVID-19 Prophylaxis

Research examined the use of the drug to explore prophylaxis against infection in adult participants who were living with confirmed COVID-19 patients. The studies monitored the incidence of subsequent PCR-confirmed SARS-CoV-2 infection over defined time intervals. This evidence was reviewed by a national regulator, which supported the establishment of a specific indication for prophylaxis.

Long-Term Studies and Follow-Up Duration

Research highlights changes measured during the study period, but data are still emerging regarding sustained outcomes over extended periods once the acute illness has passed. The initial evidence for both ARVI/Influenza and COVID-19 largely focuses on outcomes measured over defined time intervals that span the active infection period.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Triazavirin (FAQ)

Q: How long does it take for Triazavirin to start working or show effects?

A: Clinical studies involving Triazavirin track the time it takes for study participants to experience clinical endpoints, such as the reduction of fever and general clinical improvement. However, a specific, universally stated onset time for the drug's therapeutic effect is not consistently provided across all official product documents.

Q: Is Triazavirin a derivative of guanosine or a nucleoside analog?

A: Scientific and chemical classification databases indicate the active ingredient, Riamilovir, is considered a guanosine nucleotide analog. It is categorized as a synthetic chemical belonging to the azolotriazine class of antiviral compounds.

Q: Can I stop taking the medicine early if my symptoms improve?

A: Official product information establishes a fixed duration for the course of treatment. The regulatory label does not include instructions allowing or recommending early discontinuation, even in cases where symptoms may have improved. The fixed duration is part of the prescribed procedure for using the medication.

Q: What are the specific storage temperature requirements for Triazavirin?

A: The official product labeling requires the medication be stored according to the specific conditions and temperature range printed on its original packaging. This is necessary to maintain the drug’s stability and potency as established by the manufacturer.

Q: Are there any known serious, life-threatening side effects (e.g., anaphylaxis, organ failure)?

A: The safety profile does note that patients with pre-existing severe organ impairment, such as liver or kidney disease, should not use the drug. While the appearance of severe side effects is a criterion for withdrawal from clinical studies, the specific identity of rare, life-threatening events is not publicly classified in the documented list of known adverse reactions.

Q: Is Triazavirin a prodrug, and how is it activated inside the body?

A: Official labeling states that Riamilovir is a prodrug, meaning it must be converted inside the body to become active. This activation requires a chemical change called biotransformation, which is carried out by host cell kinases (enzymes) inside the cells.

Q: Is Triazavirin approved or studied for viral infections other than influenza and ARVI?

A: The core official indications for Triazavirin are the treatment of Influenza and general Acute Respiratory Viral Infections (ARVI). However, the drug has also been studied for investigational uses in other conditions, including prophylaxis and treatment studies for COVID-19.

How should Triazavirin be stored and disposed of?

How to Store and Dispose of Triazavirin

This medication must be stored according to the specific conditions and temperature ranges stated on its official packaging and labeling. As a general rule for most medicines, the product should be kept in a cool, dry place and protected from extreme heat and moisture to maintain its stability and potency.

Storage Requirements

Keep out of the sight and reach of children and pets to prevent accidental ingestion or misuse.
Retain the medicine in its original container until the time of disposal.

Disposal Instructions

The safest method for disposing of unused or expired Triazavirin is through a community drug take-back program.
If a take-back program is unavailable, mix the medicine with an unappealing substance, such as used coffee grounds or kitty litter, seal it in a bag or container, and place it in the household trash.
Do not flush the medication down a toilet or pour it into a sink unless the official label explicitly instructs otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Russia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z